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Abstract:
Physiologically-based pharmacokinetic (PBPK) modelling is a commonly used strategy in the drug development and regulatory submissions. This commentary provides a critical overview of the current status of PBPK methodologies to predict transporter-mediated pharmacokinetics, in addition to impact of disease and genetics with respect to local and systemic concentration.
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3 Physiologically-based pharmacokinetic (PBPK) modelling is now commonly used strategy in the drug development and regulatory submissions [1] [2] [3] [4] [5] [6] . A number of recent reports summarized current status on the use and predictive performance of PBPK modelling, and identified challenges in predicting complex metabolic drug-drug interactions (DDI) 7, 8 . However, confidence in predictive performance of transportermediated pharmacokinetics/DDIs, enzyme-transporter-interplay and changes in both systemic and tissues exposure associated with these scenarios is yet to be adequately established.
Although fold change in the systemic exposure of a victim drug is a common metric to assess the magnitude of DDIs 9 , this method may have limitations for interpreting certain transporter-mediated DDIs, as seen in metformin case. Metformin is recommended as the first-line pharmacotherapy for type 2 diabetes; its renal clearance and hepatic disposition are governed by transporter-mediated processes via organic cation transporter/multidrug and toxin extrusion protein (OCT/MATE). Metformin hepatic exposure during OCT/MATE modulation may not necessarily change in proportion to systemic drug concentrations, resulting in scenarios with minimal or no alterations in metformin systemic PK, yet potentially increased liver exposure and subsequently glucose lowering (PD) effect 10, 11 . In this case, it would be more relevant to quantify changes in drug exposure in tissues than in systemic circulation, which is challenging.
PBPK approach provides one key advantage in addressing this disconnect; it comes from the ability of these models to simulate tissue concentration-time profiles and gain mechanistic insight into the interplay of multiple processes (e.g., uptake and metabolic/biliary elimination) in different organs [12] [13] [14] . One excellent example of using PBPK to predict a drug's tissue PK is an integrated population PBPK model of simvastatin that incorporated complex lactone-acid inter-conversion in different tissues 15 . Subsequently, this simvastatin model was evaluated by perturbing the system to investigate the effect of reduced organic anion transporting polypeptide (OATP) 1B1 activity (SLCO1B1 c.521T>C) and inhibition of metabolism via cytochrome P450 (CYP) 3A4 (both reversible and irreversible mechanisms and contribution of parent and inhibitory metabolite were considered). Both scenarios are clinically relevant and have been associated with the development of simvastatin-induced myopathy in patients. In all the cases above, changes in both lactone and acid forms were simulated not only at the systemic level, but
also in the tissues of interest selected either due to efficacy/DDI concerns (liver) or safety (muscle).
Validation of such simulated tissue profiles is particularly challenging. However, predicted changes in simvastatin lactone/acid tissue exposure supported clinically observed cholesterol lowering effects and muscle toxicity in the scenarios tested, providing indirect evidence of the model validity. Predicted changes in simvastatin acid liver exposure are supported by understanding of the rate limiting processes affecting its liver disposition provided by the model, as metabolic clearance, rather than active uptake, determines its liver AUC (for underlying principles reader is referred to 13, 15, 16 ). Predicted simvastatin acid liver AUC is only marginally affected (decreased by 2%) in 521CC homozygotes relative to the wild type, despite substantial increase in the systemic concentrations ( Figure 1 ). This model prediction implies that cholesterol lowering efficacy of simvastatin depends on liver drug exposure and has no association with OATP1B1 polymorphism 17 . Opposite is seen in the case of metabolic inhibition, where PBPK model predicted substantial increase in simvastatin acid liver exposure, in agreement with enhanced cholesterol reduction when simvastatin is co-administrated with some CYP3A4 inhibitors (e.g., diltiazem) 15 .
Simvastatin dose reduction in the case of decreased OATP1B1-mediated uptake (due to either polymorphism or OATP-inhibition) can reduce the risk of muscle toxicity, but patients may receive a subtherapeutic dose (simvastatin acid liver exposure is unaffected by the decrease in active uptake clearance). Large scale clinical data are needed to further investigate and validate these model derived conclusions.
Advantages of integrated population PBPK modelling
Despite advances in complexity of in vitro cellular systems and modelling of transporter kinetic data, this "bottom-up" approach often results in the under-prediction of clearance 14, 18 . Reduction in OATP activity/expression due to hepatocyte isolation, cryopreservation, OATP genotype of the donor or culturing time may all contribute to this trend. In addition, in vitro-in vivo extrapolation of transporter kinetic data needs to account for differences in the transporter expression between the cellular system used and the tissue of interest (in a form of relative expression factors) 19, 20 . Uncertainty has also been reported in inhibition parameters for some of the transporters; multiple methodological considerations are currently
considered, including pre-incubation step, addition of albumin and mechanistic modeling of inhibition data for efflux transporters 12, 14, 21 .
Furthermore, it is vital to appreciate the importance of suitable clinical PK data for either verification of the developed PBPK model ('learn and confirm') or refinement of transporter parameters associated with high uncertainty (a "middle-out" approach). Alternatively, in the instances when no in vitro kinetic data are available for a transporter of interest, one can directly apply clinical PK data to estimate these parameters (a "top-down" method) 14, 22 . However, this approach introduces some methodological challenges. Plasma data may be insufficient to inform all parameters of the model, raising identifiability concerns, often manifested in increased uncertainty (standard errors) in the parameter estimates and/or problems in the optimization routines to converge to a minimum. In addition, parameter estimation generally does not account for any uncertainty in other model parameters; these are often fixed during fitting and assumed to be correct 15, 21, 22 . Sensitivity analysis performed on repaglinide PBPK model illustrates nicely this point.
Multiple solutions of 'optimized' repaglinide active hepatic uptake clearance can describe its plasma concentration-time profiles almost equally well, conditional on different values used for the fixed parameters (passive diffusion and metabolic clearance) 23 . Despite inability to differentiate models on the systemic level, repaglinide liver exposure was substantially different across scenarios investigated, raising concerns if the PBPK model was to be used subsequently for the prediction of DDIs. In addition to liver, requirement for suitable clinical data for validation/estimation of renal uptake and efflux transport parameters has been discussed 24 . For example, use of urine rather than plasma data is necessary for the optimization of MATE kinetic parameters and relative expression factor considering its localization on the apical membrane of renal proximal tubule cell 25 .
To overcome the use of fixed parameters, the integrated population PBPK approach has been introduced 15, 23, 26 . This approach combines physiologically-based approach with nonlinear mixed effects modelling and overcomes the reliance on fixed parameter by using a Bayesian framework. In this method, priors are updated using rich clinical data ('reverse translation') resulting in a statistical distribution of the output parameters, rather than just a single estimate. Emerging data on tissue concentrations (e.g., PET
imaging) 27 combined with integrated population PBPK modelling is seen as a powerful tool for 
Extension of PBPK models to predict PK in special populations
Recent analysis indicated that >40% of drugs approved in 2013-2014 lack any dose recommendations for patients with severe renal impairment 7, 28 , highlighting a need for validated PBPK models to predict the impact of pathophysiological changes associated with chronic kidney disease. Despite recent increased efforts (cidofovir, rivaroxaban, metformin, lesinurad 25, 29, 30 ), many challenges still exist. Knowledge gaps are particularly evident in physiological/system data (e.g., transporter expression and proximal tubule cellularity in diseased kidneys), mechanistic in vitro renal transporter parameters and understanding of mechanism(s) causing changes in transporter-mediated secretion in renal impairment 24, [31] [32] [33] [34] . Reduced proximal tubule cellularity, reduced transporter expression or inhibition of renal transporters by uremic solutes have all been explored as potential mechanisms using PBPK 30, 35 . Recent examples highlighted that different mechanisms considered in PBPK models for renal impairment each caused comparable net effect on the predicted systemic exposure and renal clearance of cidofovir and digoxin 30, 35 . However, predicted dynamics inside proximal tubule cells were different depending on the assumption made, emphasizing that misspecification of mechanism in the model may have severe consequences for prediction of nephrotoxicity or transporter-mediated DDIs in renally-impaired patients 35 .
Similarly, predictive performance of PBPK is generally considered low with regard to hepatic impairment (HI). A good example that highlights this challenge is the model-based prediction of liver exposure of obeticholic acid (OCA) in subjects with HI. OCA is a modified form of an endogenous bile acid chenodeoxycholic acid (CDCA) in humans and was recently approved in the US and the EU for the treatment of primary biliary cirrhosis 36, 37 . Plasma exposures of OCA and its glyco-and tauro-conjugates (glyco-OCA and tauro-OCA) are significantly increased in subjects with varying degrees of HI compared to subjects with normal liver function. The magnitude of increase in plasma exposure makes it challenging to adjust drug dose proportional to/ based on plasma exposure changes in subjects with HI. For example, the mean increases in AUC were 7, 11, and 37, and 17-fold for OCA, glyco-OCA, tauro-OCA, and total M A N U S C R I P T
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OCA (parent and two conjugates), respectively in subjects with severe HI compared to healthy subjects.
The PBPK model for OCA and its conjugates considered hepatic metabolism, permeation, and active transport of test species between the circulatory, hepatobiliary, and enteral compartments. Parameter changes associated with HI were either fixed in the OCA PBPK model (known ones, e.g., liver volume and hepatic blood flow) or estimated (unknown ones such as hepatic uptake and conjugation) using observed plasma PK of OCA and conjugates in HI subjects 38, 39 . The models were verified using external
(not used for model development) plasma PK data in healthy and HI subjects 40 . Only 2-fold increase in liver exposure of total OCA was predicted in subjects with severe HI compared to healthy, despite a much higher (13-fold) increase in plasma exposure ( Figure 2) ; the latter is consistent with the observed clinical data (17-fold) 39, 40 .
To support its prediction of liver exposure, the applicant simulated endogenous CDCA and its conjugates using the same system parameters as for OCA. The simulated AUC ratios of total CDCA (severe HI/healthy) in plasma and liver generally agreed with the reported values comparing subjects with end-stage cholestasis or cirrhosis and healthy subjects. Based on the model-predicted moderate changes in liver OCA exposures, the applicant proposed that "no dose adjustment is required in patients with hepatic impairment" 
Future directions
Pediatric population is another cohort of patients in need for increased model-driven dose recommendation in the label 41 . Emerging transporter expression data 19, 20, 42 , together with the information on transporter ontogeny 43, 44 are expected to refine current model system parameters and transporter 
